# Safety and Efficacy Study of IMSA101 in Refractory Malignancies

> **NCT04020185** · PHASE1,PHASE2 · COMPLETED · sponsor: **ImmuneSensor Therapeutics Inc.** · enrollment: 40 (actual)

## Conditions studied

- Solid Tumor, Adult

## Interventions

- **DRUG:** IMSA101
- **DRUG:** Immune checkpoint inhibitor (ICI)
- **DRUG:** Immuno-oncology (IO) therapy

## Key facts

- **NCT ID:** NCT04020185
- **Lead sponsor:** ImmuneSensor Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-23
- **Primary completion:** 2023-09-15
- **Final completion:** 2023-09-15
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2024-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04020185

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04020185, "Safety and Efficacy Study of IMSA101 in Refractory Malignancies". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04020185. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*